Recombinant Human Perq Amino Acid-Rich With Gyf Domain-Containing Protein 2 (GIGYF2) Protein (His)

Beta LifeScience SKU/CAT #: BLC-10409P
Greater than 90% as determined by SDS-PAGE.
Greater than 90% as determined by SDS-PAGE.

Recombinant Human Perq Amino Acid-Rich With Gyf Domain-Containing Protein 2 (GIGYF2) Protein (His)

Beta LifeScience SKU/CAT #: BLC-10409P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Perq Amino Acid-Rich With Gyf Domain-Containing Protein 2 (GIGYF2) Protein (His) is produced by our Yeast expression system. This is a protein fragment.
Purity Greater than 90% as determined by SDS-PAGE.
Uniprotkb Q6Y7W6
Target Symbol GIGYF2
Synonyms GIGYF2; KIAA0642; PERQ2; TNRC15GRB10-interacting GYF protein 2; PERQ amino acid-rich with GYF domain-containing protein 2; Trinucleotide repeat-containing gene 15 protein
Species Homo sapiens (Human)
Expression System Yeast
Tag N-6His
Target Protein Sequence ERLASKLQEHRAKGVSIPLMHEAMQKWYYKDPQGEIQGPFNNQEMAEWFQAGYFTMSLLVKRACDESFQPLGDIMKMWGRVPFSPGPAPPPHMGELDQERLTRQQELTALYQMQHLQYQQFLIQQQYAQVLAQQQKAALSSQQQQQLALLLQQFQTLKMRISDQNIIPSVTRSVSVPDTGSIWELQPTASQPTVWEGGSVWDLPLDTTTPGPALEQLQQLEKAKAAKLEQERREAEMRAKREEEERKRQEELRRQQEEILRRQQEEERKRREEEELARRKQEEALRRQREQEIALRRQREEEERQQQEEALRRLEERRREEEERRKQEELLRKQEEEAAKWAREEEEAQRRLEENRLRMEEEAARLRHEEEERKRKELEVQRQKELMRQRQQQQEALRRLQQQQQQQQLAQMKLPSSSTWGQQSNTTACQSQATLSLAEIQKLEEERERQLREEQRRQQRELMKALQQQQQQQQQKLSGWGNVSKPSGTTKSLLEIQQEEARQMQKQQQQQQQHQQPNRAR
Expression Range 510-1030aa
Protein Length Partial
Mol. Weight 64.6kDa
Research Area Signal Transduction
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Key component of the 4EHP-GYF2 complex, a multiprotein complex that acts as a repressor of translation initiation. In the 4EHP-GYF2 complex, acts as a factor that bridges EIF4E2 to ZFP36/TTP, linking translation repression with mRNA decay. Also recruits and bridges the association of the 4EHP complex with the decapping effector protein DDX6, which is required for the ZFP36/TTP-mediated down-regulation of AU-rich mRNA. May act cooperatively with GRB10 to regulate tyrosine kinase receptor signaling, including IGF1 and insulin receptors.
Protein Families GIGYF family
Database References

HGNC: 11960

OMIM: 607688

KEGG: hsa:26058

STRING: 9606.ENSP00000387170

UniGene: PMID: 27157137

  • required, this finding may shed light on the GIGYF2-associated mechanisms that lead to PD and suggests insulin dysregulation as a disease-specific mechanism for both PD and cognitive dysfunction. PMID: 26134514
  • Results suggest that the N56S and N457T of GIGYF2 are risk factors for Parkinson's disease in Caucasians, but not in Asians PMID: 26152800
  • GIGYF2 and the zinc finger protein 598 (ZNF598) are identified as components of the 4EHP complex. PMID: 22751931
  • Our result indicated that SCNA, LRRK2, UCHL1, HtrA2 and GIGYF2 genes' mutations might not be a main reason for Chinese Autosomal dorminant Parkinson's disease PMID: 22503729
  • within the Chinese population, the c.297T>C p.Ala99Ala polymorphism of the GIGYF2 gene may be associated with an increased risk of developing Parkinson disease. PMID: 22115759
  • These data, together with those recently reported by other groups, suggest that GIGYF2 is unlikely to be the PARK11 gene. PMID: 20060621
  • No clearly pathogenic mutations are identified in GIGYF2 and ATP13A2 in Brazilian patients with early-onset Parkinson's disease. PMID: 20816920
  • The results of this study did not support a role for GIGYF2 in the genetic etiology of Belgian Parkinson disease. PMID: 19321232
  • GIGYF2 is unlikely to play a major role in PD in Japanese patients, similar to other populations. PMID: 20641165
  • our findings suggest that GIGYF2 variants are not a frequent cause of Parkinson's disease in the Spanish population, since we found no clearly segregating GIGYF2 variants PMID: 19845746
  • GIGYF2 variants are not associated with Parkinson's disease in the mainland Chinese Population. PMID: 20044296
  • The results of this study do not support a major role of GIGYF2 in parkinson disease. PMID: 20004041
  • We identified nine novel variants in GIGYF2 gene, which might be associated with PD in the Chinese population. PMID: 20178831
  • These data strongly support GIGYF2 as a PARK11 gene with a causal role in familial Parkinson disease. PMID: 18358451
  • Mutations in GIGYF2 are not strongly related to the development of the Parkinson's disease in Portuguese and North American populations. PMID: 18923002
  • This study suggested that reported mutations in GIGYF2 are not a common cause of Parkinson's disease in Norway and United States. PMID: 19133664
  • The results of this study concluded that neither of Asn56Ser and Asn457Thr variants plays a major role in the pathogenesis of parkinson disease. PMID: 19250854
  • We believe that variation in a gene other than GIGYF2 accounts for the previously reported linkage finding on chromosome 2q36-37. PMID: 19279319
  • The current genetic evidence suggestes that GIGYF2 is not a common cause od parkinson disease in several Caucasian. PMID: 19348706
  • GIGYF2 Asn56Ser and Asn457Thr mutations are a rare cause of PD in North American Caucasian population PMID: 19429085
  • analysis of GIGYF2 variants in Parkinson's disease from two Asian populations PMID: 19449032
  • GIGYF2 mutations are not a frequent cause of Parkinson's disease PMID: 19482505
  • This letter suggested that GIGYF2 is neither responsible for PARK11 nor a gene implicated in Parkinson disease. PMID: 19562763
  • The GIGYF2 Asn56Ser mutation is rare in Chinese PD patients. PMID: 19638301
  • FAQs

    Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

    Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

    Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

    Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

    Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

    Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

    To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

    Recently viewed